Coreline Soft Wins 'Korean National Lung Cancer Screening Project' for 9 Consecutive Years Following Adoption in the UK and France

[Financial News]  Coreline Soft has recently strengthened its global sales through the Microsoft (MS) subsidiary Nuance and is expanding its supply in European countries such as the UK, France, and Germany, while also securing continuous achievements domestically.
Coreline Soft announced on the 29th that it will supply artificial intelligence (AI) software (SW) for the national lung cancer screening project organized by the National Cancer Center for the 9th consecutive year.
Coreline Soft has been supplying its own AI SW 'AVIEW LCS Plus' since the pilot project for national lung cancer screening in 2017. Recognized for its excellent product competitiveness and high interoperability by the National Cancer Center, it continues to deliver AI products even after the official introduction of lung cancer screening in national cancer screening.
Coreline Soft is accelerating its global market penetration as well as domestically. Recently, it was selected for the 'Eastern Diagnostic Imaging Network (EDIN)' project of the UK's National Health Service and 'IMPULSION' organized by the French National Cancer Institute, successfully establishing itself as a core solution for lung cancer screening programs in major European countries. Additionally, it has formed partnerships with MS subsidiary Nuance and German pharmaceutical company Bayer's AI platform, expanding the deployment of solutions in hospitals in North America and Europe.
Jin-guk Kim, CEO of Coreline Soft, said, “We are expanding major overseas projects and cloud data ecosystems based on unique references,” adding, “We will establish ourselves as a key AI partner in additional countries within the UK, France, Germany, and the European Union (EU), leading the global standard for lung cancer screening.”
He continued, “AI not only automates the entire diagnostic process but also maximizes the accuracy of screenings conducted nationwide based on excellent interoperability, which is why Coreline Soft's AI products continue to be adopted in the national lung cancer screening project,” adding, “It is rare for an AI company to analyze multiple diseases with a single product and have experience in long-term operation with public institutions, so supply will expand to the US and Middle East markets in the future.”
Meanwhile, Germany has verified the clinical efficacy of AI introduction in the field of lung cancer screening through the 'HANSE' project conducted by Coreline Soft and recently announced an official guideline recommending the use of AI for the first reading. National or public unit screening projects are also underway in Australia, Finland, Poland, Norway, and the company explained that bidding and pilot tests are being conducted in parallel.


kakim@fnnews.com Kyung-a Kim Reporter